TURKU, Finland, Aug. 19, 2021 /PRNewswire/ -- DelSiTech Ltd, the leader in silica based ophthalmic drug delivery technologies with its headquarters in Turku, Finland, and Visus Therapeutics, Inc., a Seattle-based American clinical-stage company developing innovative eye care solutions for patients globally, today announced an exclusive licensing and collaboration agreement pertaining to the development of a range of novel long-acting ocular therapeutics. The agreement, exclusive to therapeutic assets held by Visus Therapeutics, signals the continued commitment of both parties to develop leading solutions for patients around the world across six unique development programs targeting the management of ocular diseases of the back and front of the eye.
Management of ocular disorders affecting the posterior segment continues to pose a central challenge in drug development today. Ailments can be highly debilitating and significantly lessen patients' quality of life or even lead to blindness if left untreated, while treatments remain highly invasive. Additionally, ocular diseases of the anterior segment can be equally debilitating and represent significant burdens on public health; however, current treatment options can be extremely inefficient with regimens requiring excessive daily dosing, a regimen that is also often deviated from due to lifestyle and routine, hindering the treatment's efficacy.
The development of effective remedies, while challenging, relies heavily on innovative approaches taken by ophthalmology centric companies such as Visus Therapeutics. Furthermore, the need for long-term therapeutic relief for typically chronic ocular disorders has remained largely unaddressed, perpetuating the significant treatment burdens experienced by patients receiving frequent intra-ocular injections or demanding topically administered regimens.
"By expanding our portfolio to include investigational drugs for glaucoma and age-related macular degeneration and leveraging this innovative drug delivery technology, Visus is well positioned to develop a new generation of therapies that could potentially change the standard of care for these sight-threatening conditions," said Ben Bergo, co-founder and Chief Executive Officer at Visus Therapeutics. "This represents a significant step forward in our strategy as we evolve into an innovation-driven ophthalmic platform company armed with differentiated, patent-protected assets driven by a world-class leadership team."
DelSiTech's Silica Matrix, an innovative drug delivery technology platform, enables the long-acting controlled release of both small drug molecules as well as biologics in a wide range of tissues, including the intravitreal space inside the eye, for durations in excess of several months, presenting an alternative to frequent invasive procedures, or in the case of topical treatments, truly once daily dosing. Many small molecule drugs are poorly retained in the eye, often eliminated in a matter of hours from the vitreous body or less in the case of topically administered treatments. In these instances, a controlled release dosage form would be the only viable option for treating the diseases of the posterior and anterior segment.
Dr. Lasse Leino, Chief Executive Officer of DelSiTech commented, "DelSiTech has a long-standing keen focus on ophthalmic drug delivery, as an area where we feel that patients still remain largely unsupported. This critical unmet need continues to motivate us to forge alliances with leading ophthalmic drug developers such as Visus Therapeutics, who are able to create solutions at the forefront of ophthalmic research. We are truly excited to be playing a role in the future of long-acting ophthalmic medicines, now with this agreement, across such a substantive range of products."
About DelSiTech
DelSiTech Ltd., located in Turku, Finland, is the leading technology specialist in biodegradable silica-based controlled release of small molecule drugs, biologics and viral vectors. It develops and commercializes its proprietary, drug delivery technology in collaboration with a number of pharma and biotech companies to turn their ideas into novel drug products. For more information, see www.delsitech.com.
About DelSiTechTM Silica Matrix
Silica Matrix is an advanced delivery technology platform for parenteral and local administration of injectable and implant dosage forms as well as eye drops. The proprietary technology is based on silica (SiO2) matrix into which the molecule or therapeutic agent of interest is embedded using a process called sol-gel. The resulting Silica Matrix is non-porous, biocompatible and it can be designed to biodegrade by matrix dissolution at the desired rate to ensure a tightly controlled release of the active substance over periods of days up to many months or a year.
About Visus Therapeutics
Visus Therapeutics is a clinical-stage company focused on developing innovative ophthalmic therapies to improve vision for people around the world. With offices in Seattle and Orange County, Calif., its lead clinical candidate is BRIMOCHOL, an investigational drug designed to be a once-daily eye drop to correct for the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates with applications in ocular surface disease, glaucoma and age-related macular degeneration. For more information, visit www.visustx.com.
